PIXUVRI® Launched In UK For Adult Patients With Multiply Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

     PIXUVRI® Launched In UK For Adult Patients With Multiply Relapsed Or
              Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

  PR Newswire

  BIRMINGHAM, England, April 29, 2014

- First and Only Approved Monotherapy in the EU for this Patient Population -

BIRMINGHAM, England, April 29, 2014 /PRNewswire/ --Cell Therapeutics, Inc.
(CTI) (NASDAQ and MTA: CTIC) today announced the launch of PIXUVRI®
(pixantrone), the first new treatment for adult patients in the United Kingdom
(UK) with multiply relapsed or refractory aggressive B-cell non-Hodgkin
lymphoma (aggressive B-cell NHL), at the 54 ^th annual scientific meeting of
the British Society for Haematology.

PIXUVRI is the first monotherapy treatment option for this patient group and
the only therapy licensed for third and fourth line use in aggressive B-cell
NHL patients, which includes diffuse large B-cell lymphoma (DLBCL). There are
approximately 37,000 new cases of aggressive B-cell NHL every year in the
European Union (EU) ^[1,2] , and CTI estimates that up to 1,600 to 1,800
people in the UK are diagnosed with aggressive B-cell NHL each year. Patients
with aggressive B-cell NHL who relapse after second-line treatment have a poor
survival prognosis ranging from only several weeks to 12 months. ^[3,4]

Professor Finbarr E. Cotter, Professor of Haematology and Chair of
Experimental Haematology, Centre for Haemato-Oncology, Barts Cancer Institute,
and representative for the British Society for Haematology (BSH) said, "The
availability of PIXUVRI in the UK is an important milestone for patients who
have aggressive B-cell NHL. DLBCL is the most common type of aggressive NHL
and despite undoubted progress in the last 10 years resulting from the
introduction of better first-line therapy, the disease still recurs in some
patients. A new therapy that delivers effective treatment with manageable side
effects offers real hope for these patients that fail second- or third-line

PIXUVRI is a novel aza-anthracenedione with unique structural and
physiochemical properties. The PIX301 phase 3 clinical trial demonstrated
anti-lymphoma activity of PIXUVRI and a predictable and manageable side effect
profile compared to other treatments for this condition. ^[5]

James A. Bianco, M.D., President and Chief Executive Officer of CTI, said, "At
CTI, we prioritise the patient experience and are committed to developing
therapeutic options for people living with cancer who want a chance at a
longer and better quality of life. We are pleased to be able to bring PIXUVRI
to patients in the UK, addressing a critical gap in care for patients at this
stage of the disease living with few, if any effective treatment options."

The launch in the UK of PIXUVRI follows conditional marketing authorization by
the European Commission (EC) in 2012 and the National Institute for Health and
Care Excellence final guidance recommending prescription of PIXUVRI as a
cost-effective monotherapy in early 2014. PIXUVRI is currently available in
Austria, Denmark, Finland, Germany, Italy, France, Netherlands, Norway, Sweden
and the UK. CTI intends to pursue making PIXUVRI available in other European
countries in 2014.

About PIXUVRI ® (pixantrone) PIXUVRI is a novel aza-anthracenedione with
unique structural and physiochemical properties. Unlike related compounds,
PIXUVRI forms stable DNA adducts and in preclinical models has superior
anti-lymphoma activity compared to related compounds. PIXUVRI was structurally
designed so that it cannot bind iron and perpetuate oxygen radical production
or form a long-lived hydroxyl metabolite -- both of which are the putative
mechanisms for anthracycline induced acute and chronic cardiotoxicity. These
novel pharmacologic properties allow PIXUVRI to be administered to patients
with near maximal lifetime exposure to anthracyclines without unacceptable
rates of cardiotoxicity.

In May 2012, the EC granted conditional marketing authorization for PIXUVRI as
a monotherapy for the treatment of adult patients with multiply relapsed or
refractory aggressive NHL. The benefit of PIXUVRI treatment has not been
established in patients when used as fifth line or greater chemotherapy in
patients who are refractory to last therapy. The Summary of Product
Characteristics (SmPC) has the full prescribing information, including the
safety and efficacy profile of PIXUVRI in the approved indication. The SmPC is
available at www.pixuvri.eu. PIXUVRI does not have marketing approval in the
United States.

About NHL NHL is the sixth most common cancer in the UK; in 2010, 12,180
people were diagnosed with the disease. ^[6] NHL is caused by the abnormal
proliferation of lymphocytes, cells that are key to the functioning of the
immune system. It usually originates in lymph nodes and spreads through the
lymphatic system. NHL can be broadly classified into two main forms—aggressive
and indolent NHL. Aggressive NHL is a rapidly growing form of the disease that
moves into advanced stages much faster than indolent NHL, which progresses
more slowly.

There are many subtypes of NHL, but aggressive B-cell NHL is the most common
and accounts for about 55 percent of NHL cases. ^[1] After initial therapy for
aggressive NHL with anthracycline-based combination therapy, one-third of
patients typically develop progressive disease. ^[7] Approximately half of
these patients are likely to be eligible for intensive second-line treatment
and stem cell transplantation, although 50 percent are expected not to
respond. ^[7] For those patients who fail to respond or relapse following
second line treatment, treatment options are limited, and usually palliative
only. ^[7]

About Conditional Marketing Authorization Similar to accelerated approval
regulations in the United States, conditional marketing authorizations are
granted in the E.U. to medicinal products with a positive benefit/risk
assessment that address unmet medical needs and whose availability would
result in a significant public health benefit. A conditional marketing
authorization is renewable annually. Under the provisions of the conditional
marketing authorization for PIXUVRI, CTI will be required to complete a
post-marketing study aimed at confirming the clinical benefit previously

The European Medicines Agency's Committee for Medicinal Products for Human Use
has accepted PIX306, CTI's ongoing randomized controlled Phase 3 clinical
trial, which compares PIXUVRI-rituximab to gemcitabine-rituximab in patients
who have relapsed after one to three prior regimens for aggressive B‑cell NHL
and who are not eligible for autologous stem cell transplant. As a condition
of approval, CTI has agreed to have available the PIX306 clinical trial
results by June 2015.

About Cell Therapeutics, Inc. CTI (NASDAQ and MTA: CTIC) is a
biopharmaceutical company committed to the development and commercialization
of an integrated portfolio of oncology products aimed at making cancer more
treatable. CTI is headquartered in Seattle, WA. For additional information and
to sign up for email alerts and get RSS feeds, please visit
www.CellTherapeutics.com .

Forward-Looking Statements This press release includes forward-looking
statements within the meaning of the Safe Harbor provisions of the Private
Securities Litigation Reform Act of 1995. Such statements are subject to a
number of risks and uncertainties, the outcome of which could materially
and/or adversely affect actual future results and the trading price of CTI's
securities. Such statements include, but are not limited to, statements
regarding CTI's expectations with respect to the development of CTI and its
product and product candidate portfolio, the expected number of people in the
EU and UK with multiply relapsed aggressive B-cell NHL per year and the
survival prognosis, the expected benefits and effectiveness of PIXUVRI and the
potential availability of PIXUVRI in other European countries during 2014.
Risks that contribute to the uncertain nature of the forward-looking
statements include, among others, risks associated with the biopharmaceutical
industry in general and with CTI and its product and product candidate
portfolio in particular including, among others, risks associated with the
following: that CTI cannot predict or guarantee the pace or geography of
enrollment of its clinical trials, that CTI cannot predict or guarantee the
outcome of preclinical and clinical studies, that CTI may not obtain
reimbursement for PIXUVRI in certain markets in the EU as planned, that the
conditional marketing authorization for PIXUVRI may not be renewed, that CTI
may not obtain favorable determinations by other regulatory, patent and
administrative governmental authorities, that CTI may experience delays in the
commencement of preclinical and clinical studies, risks related to the costs
of developing, producing and selling PIXUVRI and CTI's other product
candidates, and other risks, including, without limitation, competitive
factors, technological developments, that CTI's operating expenses continue to
exceed its net revenues, that CTI may not be able to sustain its current cost
controls or further reduce its operating expenses, that CTI may not achieve
previously announced goals and objectives as or when projected, that CTI's
average net operating burn rate may increase, that CTI will continue to need
to raise capital to fund its operating expenses, but may not be able to raise
sufficient amounts to fund its continued operation as well as other risks
listed or described from time to time in CTI's most recent filings with the
Securities and Exchange Commission on Forms 10-K, 10-Q and 8-K. Except as
required by law, CTI does not intend to update any of the statements in this
press release upon further developments.

PIXUVRI® is a registered trademark of Cell Therapeutics, Inc.


1.Harris NL, et al. The World Health Organization classification of
    neoplastic diseases of the hematopoietic and lymphoid tissues. Report of
    the Clinical Advisory Committee meeting, Airlie House, Virginia, November,
    1997. Ann Oncol. 1999 Dec;10(12):1419-32.
2.European Cancer Observatory, Cancer Fact Sheets, 2008. Available at:
    http://eco.iarc.fr/EUCAN/ . Last accessed April 2014.
3.Hagemeister FB. Treatment of relapsed aggressive lymphomas: regimens with
    and without high-dose therapy and stem cell rescue. Cancer Chemother
    Pharmacol. 2002 May;49 Suppl 1:S13-20. Epub 2002 Apr 12.
4.Cabanillas F. Pixantrone: a new agent for relapsed aggressive lymphomas.
    Lancet Oncol . 2012 Jul;13(7):654-6. doi: 10.1016/S1470-2045(12)70232-2.
    Epub 2012 May 30.
5.Pettengell R. et al. Pixantrone dimaleate versus other chemotherapeutic
    agents as a single-agent salvage treatment in patients with relapsed or
    refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre,
    open-label, randomised trial. Lancet Oncol . 2012 Jul;13(7):696-706. doi:
    10.1016/S1470-2045(12)70212-7. Epub 2012 May 30.
6.Cancer Research UK, Cancer incidence for common cancers. Available at:
    Last accessed April 2014 .
7.Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma.
    Hematology Am Soc Hematol Educ Program. 2011;2011:498-505. doi:

Contacts: Monique Greer+1-206-272-4343 mgreer@ctiseattle.com

Ed Bell+1-206-282-7100 ebell@ctiseattle.com 

In EuropeCTI Life Sciences Limited, Milan BranchLaura VillaT: +39-02-0061-6550
lvilla@CTI-Lifesciences.com CTI_EUInvestors@CTI-Lifesciences.com

Website: http://www.celltherapeutics.com
Press spacebar to pause and continue. Press esc to stop.